United States Viral Vector Vaccines Market 2025 | Growth Drivers, Key Players & Investment Opportunities | Leading companies - Abbott, GlaxoSmithKline Plc, Pfizer, BioNTech

Market Size and Growth

Viral Vector Vaccines Market is growth at a CAGR of 14% during the forecast period (2024-2031).

Key Development:

United States: Recent Industry Developments

✅ In September 2025, Pfizer and BioNTech's Comirnaty® COVID-19 vaccine received full approval from the U.S. Food and Drug Administration (FDA) for adults aged 65 and older and individuals aged 5-64 with underlying conditions. The update strengthens U.S. preparedness for seasonal SARS-CoV-2 variants and immunization efforts.

✅ In August 2025, the FDA approved the 2025-2026 formula of Pfizer and BioNTech's Comirnaty®, adapted to circulating SARS-CoV-2 variants including LP.8.1. The reformulation supports continued protection against evolving COVID-19 strains.

✅ In May 2025, the National Institutes of Health announced funding for its "Generation Gold Standard" vaccine program, advancing a universal vaccine platform that includes viral vector technologies. This initiative supports next-generation innovation in viral vector-based immunization strategies across the U.S.

✅ In April 2025, researchers unveiled a novel adenovirus type-4 viral vector vaccine platform for respiratory pathogens, demonstrating strong preclinical immune responses. The breakthrough expands U.S. capabilities beyond COVID-19 toward broader viral vector vaccine applications.

✅ In March 2025, CyanVac, in collaboration with the National Institutes of Health, initiated a Phase 2b clinical trial for its intranasal viral vector vaccine candidate CVXGA1. The vaccine leverages a parainfluenza virus-5 vector to provide enhanced mucosal immunity.

✅ In February 2025, Bavarian Nordic received U.S. FDA approval for its chikungunya vaccine VIMKUNYATM, the first licensed chikungunya vaccine in the country. The approval highlights the growing acceptance and success of viral vector-based vaccine technology.

Japan: Recent Industry Developments

✅ In September 2025, Novavax, in collaboration with Takeda Pharmaceutical Company, received approval in Japan for Nuvaxovid® for use in individuals aged 6 years and older for initial vaccination and 12 years and older for boosters. The vaccine targets the Omicron LP.8.1 strain, expanding Japan's updated immunization options.

✅ In August 2025, Meiji Seika Pharma Co., Ltd. obtained manufacturing and marketing approval in Japan for a new 2-dose vial presentation of its Kostaive® self-amplifying mRNA COVID-19 vaccine. The formulation targets the Omicron JN.1 and XEC sublineages, enhancing Japan's vaccine readiness.

✅ In June 2025, the Japanese government selected a "singly replicating vaccine" project led by The University of Tokyo under the AMED SCARDA program. The initiative develops an intranasal influenza vaccine using a viral vector-style replication system, advancing Japan's vaccine R&D pipeline.

✅ In April 2025, researchers at Kanazawa University launched a next-generation viral vector vaccine project targeting Plasmodium falciparum and P. vivax malaria. The program utilizes the LC16m8Δ/AAV platform to pioneer vector-based vaccines for parasitic infections.

✅ In March 2025, Japan recognized viral vector vaccines as a strategic biotechnology focus area, spurring government investment and partnerships to enhance domestic R&D and manufacturing capabilities. The effort aims to strengthen Japan's vaccine self-sufficiency.

✅ In February 2025, the Japanese government reaffirmed its commitment to the International AIDS Vaccine Initiative (IAVI), supporting ongoing research into Sendai and VSV viral vector platforms. This continued funding underscores Japan's leadership in vector-based HIV vaccine innovation.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/viral-vector-vaccines-market?sb

Key Players:

=> Sanofi Pasteur Inc. (Sanofi S/A), AstraZeneca, CSL Ltd. (Seqirus), Abbott, GlaxoSmithKline Plc, Serum Institute of India Pvt. Ltd, Pfizer, BioNTech, F.Hoffman La Roche Ltd and Novartis.

Growth Forecast Projected:

The Global Viral Vector Vaccines Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Viral Vector Vaccines Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=viral-vector-vaccines-market

Key Segments:

➥ By Vector Type: Adeno-associated Virus, Retrovirus, Lentivirus, Adenovirus, Sendai Virus
➥ By Route of Administration: Intramuscular, Subcutaneous
➥ By Application: Gene Therapy, Vaccinology Development
➥ By Distribution Channel: Hospitals, Vaccination Centers, Specialized Clinics

Regional Analysis for Viral Vector Vaccines Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Viral Vector Vaccines producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Viral Vector Vaccines revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/viral-vector-vaccines-market?sb

FAQ

Q: What is the growth rate of the Viral Vector Vaccines Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 14% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.